Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2
Modify Date: 2025-08-27 09:50:20
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 structure
|
Common Name | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 | ||
|---|---|---|---|---|
| CAS Number | 2435572-48-6 | Molecular Weight | 534.56 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H34N4O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. |
| Name | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 |
|---|
| Description | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. |
|---|---|
| Related Catalog | |
| Target |
Cereblon |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. |
| References |
| Molecular Formula | C25H34N4O9 |
|---|---|
| Molecular Weight | 534.56 |